T Joseph Raoof MD Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,516,116	135
2024	Research	$1,053,279	82
2023	Research	$206,526	31
2022	Research	$230,316	30
2021	Research	$234,013	40
2020	Research	$490,449	73
2019	Research	$904,467	67

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $3,077,678 362 payments
Sanofi US Services Inc. $721,588 40 payments
Janssen Research & Development, LLC $376,016 22 payments
LEO Pharma AS $360,492 17 payments
Vanda Pharmaceuticals Inc. $80,902 11 payments
Genzyme Corporation $14,443 1 payment
Eli Lilly and Company $2,316 4 payments
Amgen Inc. $1,732 1 payment

Studies the money was for Research payments · program years 2019–2025

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $383,134 16 payments
M18-891 $381,814 22 payments
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $376,016 22 payments
Dose-Ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 MG/G Compared to Delgocitinib Cream Vehicle Over An 8-Week Treatment Period in Adult Subjects With Atopic Dermatitis. $355,971 13 payments
M15-997 $326,025 45 payments
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $311,969 14 payments
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD $311,792 15 payments
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $220,290 8 payments
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis $209,629 34 payments
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $187,915 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.